Literature DB >> 15102479

Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.

Valérie Ugo1, Christophe Marzac, Irène Teyssandier, Frédéric Larbret, Yann Lécluse, Najet Debili, William Vainchenker, Nicole Casadevall.   

Abstract

Polycythemia vera (PV) is a myeloproliferative disorder arising in a multipotent hematopoietic stem cell. The pathogenesis of PV remains poorly understood; however, the biologic hallmark of this disease is the presence of erythropoietin (Epo)-independent colony formation (endogenous erythroid colony [EEC]) and cytokine hypersensitivity. We have developed a simple liquid culture from CD34+ cells to study PV erythroid differentiation. PV erythroid differentiation was characterized in this culture system by two types of abnormalities: 1) an increased proliferation of progenitors in response to cytokines, associated with strict cytokine dependency for preventing apoptosis; and 2) Epo-independent terminal erythroid differentiation in the presence of stem cell factor and interleukin-3 as evidenced by the acquisition of glycophorin A. The level of Epo-independent terminal differentiation correlates in PV patients with the number of EEC. Epo-independent terminal differentiation as well as normal Epo-induced differentiation were repressed by inhibitors of JAK2 (AG490), PI3K (LY294002), and the Src family kinases (PP2). In contrast, an inhibitor of the ERK/MAP kinase pathway (PD98059) had no effect on Epo-independent terminal differentiation. These signaling abnormalities were not mediated by a decreased expression or activity of the membrane tyrosine phosphatase CD45, which dephosphorylates JAK2 and Src family kinases. This study demonstrates that early steps of PV erythroid differentiation are strictly cytokine dependent. In contrast, late erythroid differentiation is an Epo-independent phenomenon that is mediated by signaling pathways identical to those in Epo-induced differentiation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102479     DOI: 10.1016/j.exphem.2003.11.003

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  42 in total

Review 1.  Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes; Srdan Verstovsek
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

2.  Absence of JAK2 V617F mutation in thalassemia intermedia patients.

Authors:  Ali Taher; Dina Shammaa; Ali Bazarbachi; Doha Itani; Ghazi Zaatari; Layal Greige; Zaher K Otrock; Rami A R Mahfouz
Journal:  Mol Biol Rep       Date:  2008-09-10       Impact factor: 2.316

Review 3.  Myeloproliferative disorders.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

4.  Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway.

Authors:  Wei Zhao; Claire Kitidis; Mark D Fleming; Harvey F Lodish; Saghi Ghaffari
Journal:  Blood       Date:  2005-10-04       Impact factor: 22.113

5.  Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

Authors:  Paola Guglielmelli; Giovanni Barosi; Alessandro Rambaldi; Roberto Marchioli; Arianna Masciulli; Lorenzo Tozzi; Flavia Biamonte; Niccolò Bartalucci; Elisabetta Gattoni; Maria Letizia Lupo; Guido Finazzi; Alessandro Pancrazzi; Elisabetta Antonioli; Maria Chiara Susini; Lisa Pieri; Elisa Malevolti; Emilio Usala; Ubaldo Occhini; Alberto Grossi; Silvia Caglio; Simona Paratore; Alberto Bosi; Tiziano Barbui; Alessandro M Vannucchi
Journal:  Blood       Date:  2011-07-01       Impact factor: 22.113

6.  AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation.

Authors:  Saghi Ghaffari; Claire Kitidis; Wei Zhao; Dragan Marinkovic; Mark D Fleming; Biao Luo; Joseph Marszalek; Harvey F Lodish
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

Review 7.  Genetics of myeloproliferative neoplasms.

Authors:  Aaron D Viny; Ross L Levine
Journal:  Cancer J       Date:  2014 Jan-Feb       Impact factor: 3.360

8.  Synthesis and evaluation of resveratrol derivatives as fetal hemoglobin inducers.

Authors:  Priscila Longhin Bosquesi; Aylime Castanho Bolognesi Melchior; Aline Renata Pavan; Carolina Lanaro; Cristiane Maria de Souza; Radda Rusinova; Rafael Consolin Chelucci; Karina Pereira Barbieri; Guilherme Felipe Dos Santos Fernandes; Iracilda Zepone Carlos; Olaf Sparre Andersen; Fernando Ferreira Costa; Jean Leandro Dos Santos
Journal:  Bioorg Chem       Date:  2020-05-16       Impact factor: 5.275

9.  Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo.

Authors:  J A Kennedy; F Barabé; B J Patterson; J Bayani; J A Squire; D L Barber; J E Dick
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-31       Impact factor: 11.205

10.  Elevated nuclear factor erythroid-2 levels promote epo-independent erythroid maturation and recapitulate the hematopoietic stem cell and common myeloid progenitor expansion observed in polycythemia vera patients.

Authors:  Ruzhica Bogeska; Heike L Pahl
Journal:  Stem Cells Transl Med       Date:  2013-01-22       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.